Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:AMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.83-1.5%$3.76$2.90▼$11.16$338.02M0.072.93 million shs2.13 million shsAMTAmerican Tower$191.60+0.1%$196.63$172.51▼$234.33$89.57B0.863.21 million shs1.98 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-2.30%-1.03%-6.13%-44.17%AMTAmerican Tower0.00%+2.68%-0.73%-14.79%-15.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.83-1.5%$3.76$2.90▼$11.16$338.02M0.072.93 million shs2.13 million shsAMTAmerican Tower$191.60+0.1%$196.63$172.51▼$234.33$89.57B0.863.21 million shs1.98 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-2.30%-1.03%-6.13%-44.17%AMTAmerican Tower0.00%+2.68%-0.73%-14.79%-15.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.38Hold$17.40354.31% UpsideAMTAmerican Tower 2.84Moderate Buy$238.0024.22% UpsideCurrent Analyst Ratings BreakdownLatest AZV, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$250.00 ➝ $251.0010/17/2025AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$245.00 ➝ $220.0010/16/2025AMTAmerican TowerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$270.00 ➝ $235.0010/16/2025AMTAmerican TowerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $225.0010/13/2025AMTAmerican TowerJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$281.00 ➝ $226.0010/10/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/8/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AMTAmerican TowerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/1/2025AMTAmerican TowerRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform ➝ Sector Perform$260.00 ➝ $220.0010/1/2025AMTAmerican TowerRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$260.00 ➝ $220.009/27/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,901.79N/AN/A$1.74 per share2.20AMTAmerican Tower$10.13B8.86$11.60 per share16.52$20.64 per share9.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)AMTAmerican Tower$2.26B$2.7569.6719.161.1612.60%24.85%4.01%10/28/2025 (Confirmed)Latest AZV, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025ALTAltimmune-$0.29N/AN/AN/A$0.00 millionN/A10/28/2025Q3 2025AMTAmerican Tower$2.64N/AN/AN/A$2.65 billionN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million7/29/2025Q2 2025AMTAmerican Tower$2.59$2.60+$0.01$2.60$2.58 billion$2.63 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.55%N/A247.27%1 YearsLatest AZV, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/18/2025AMTAmerican Towerquarterly$1.703.55%9/30/20259/30/202510/20/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44AMTAmerican Tower3.360.950.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%AMTAmerican Tower0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableAMTAmerican Tower4,691468.25 million467.46 millionOptionableAZV, ADR, AMT, and ALT HeadlinesRecent News About These CompaniesCitigroup Cuts American Tower (NYSE:AMT) Price Target to $225.001 hour ago | americanbankingnews.comMorgan Stanley Cuts American Tower (NYSE:AMT) Price Target to $235.001 hour ago | americanbankingnews.comAnalysts Are Bullish on Top Real Estate Stocks: Prologis (PLD), American Tower (AMT)October 18 at 1:25 PM | theglobeandmail.comAnalysts Offer Insights on Real Estate Companies: Crown Castle (CCI) and American Tower (AMT)October 18 at 1:25 PM | theglobeandmail.comAmerican Tower (NYSE:AMT) Given New $220.00 Price Target at BMO Capital MarketsOctober 18 at 9:35 AM | marketbeat.comChevy Chase Trust Holdings LLC Grows Holdings in American Tower Corporation $AMTOctober 18 at 5:32 AM | marketbeat.comBarclays Maintains American Tower (AMT) Overweight RecommendationOctober 18 at 3:24 AM | msn.comAmerican Tower's Q3 2025 Earnings: What to ExpectOctober 17 at 9:10 AM | barchart.comEasterly Investment Partners LLC Makes New Investment in American Tower Corporation $AMTOctober 17 at 7:11 AM | marketbeat.comKoa Wealth Management LLC Decreases Stock Holdings in American Tower Corporation $AMTOctober 17 at 7:00 AM | marketbeat.comNordea Investment Management AB Acquires 15,920 Shares of American Tower Corporation $AMTOctober 17 at 5:54 AM | marketbeat.comAtria Wealth Solutions Inc. Cuts Stake in American Tower Corporation $AMTOctober 17 at 4:14 AM | marketbeat.comAmerican Tower Corporation $AMT Shares Purchased by Cwm LLCOctober 17 at 3:51 AM | marketbeat.comCitigroup Maintains American Tower (AMT) Buy RecommendationOctober 17 at 3:41 AM | msn.comSmart Money's Big Bet on AST SpaceMobile (AMT)...October 16 at 2:55 PM | marketbeat.comAmerican Tower price target lowered to $225 from $250 at CitiOctober 16 at 1:51 PM | msn.comAmerican Tower price target lowered to $235 from $270 at Morgan StanleyOctober 16 at 1:51 PM | msn.comMorgan Stanley Lowers American Tower (NYSE:AMT) Price Target to $235.00October 16 at 9:49 AM | marketbeat.comCitigroup Has Lowered Expectations for American Tower (NYSE:AMT) Stock PriceOctober 16 at 8:26 AM | marketbeat.comBridges Investment Management Inc. Reduces Stake in American Tower Corporation $AMTOctober 16 at 5:52 AM | marketbeat.comAmerican Tower Corporation $AMT Shares Bought by New York State Teachers Retirement SystemOctober 16 at 5:51 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Bargain Alert on 3 Stocks Investors Have OversoldBy Nathan Reiff | September 29, 2025QURE: Why Analysts See Up to 63% Upside After 250% Single-Day PopBy Leo Miller | October 3, 2025AZV, ADR, AMT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$3.83 -0.06 (-1.54%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.86 +0.02 (+0.65%) As of 10/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American Tower NYSE:AMT$191.60 +0.13 (+0.07%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$191.48 -0.12 (-0.06%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
